Remy Burcelin

Metabolic and Cardiovascular Diseases
INSERM-French Institute of Health and Medical Research
France

Biography

He is a director of Institut des Maladies Métaboliques et Cardiovasculaires. Dr. Brucelin's team aims at identifying the intestinal risk factors which control glycemia, dyslipidemia and heart failure.

Research Intrest

Biotechnology, Cell Biology, Endocrinology

List of Publications
Grasset, E., Puel, A., Charpentier, J., Collet, X., Christensen, J. E., Tercé, F., & Burcelin, R. (2017). A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism. Cell Metabolism, 25(5), 1075-1090.
Wu, H., Esteve, E., Tremaroli, V., Khan, M. T., Caesar, R., Mannerås-Holm, L., ... & Xifra, G. (2017). Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nature Medicine.
Grasset, E., Puel, A., Charpentier, J., Collet, X., Christensen, J. E., Tercé, F., & Burcelin, R. (2017). A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism. Cell Metabolism, 25(5), 1075-1090.